Veradermics, Incorporated (MANE) Stock Price

Live Veradermics, Incorporated Stock Price, Historical MANE Stock Price Chart

24H Range
 
 
 
52W Range
 
 
 
Last Price $ 129.66
Open $ 134.06
Previous Close $ 135.29
Volume $ 121.59M
ATH $ 156.69 (-17.25%)
ExchangeNYSE
P/E Ratio (TTM) -37.47
EPS (TTM) -$ 3.46
Annual Dividend (Yield) -
Market Cap $ 5.47B
Veradermics, Incorporated Performance
Prev. Close 7 Days 1 Month 3 Months 6 Months 1 Year YTD 5 Year Max
-4.16% -9.93% 12.68% 19.81% 29.17% 243.47% 243.47% 243.47% 243.47%

About Veradermics, Incorporated

Statistics

The Veradermics, Incorporated stock price is currently $ 129.66 with a total market cap valuation of $ 5.47B (42.20M shares outstanding). The Veradermics, Incorporated is trading on NYSE under the ticker sign MANE. Veradermics, Incorporated price is up -4.16% in the past 24 hours. The Veradermics, Incorporated stock price prediction is currently bullish.

Description

Company Profile

News

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 '302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

MANE
Veradermics, Incorporated
$ 129.66
-9.93%   Last 7D
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Updated a day ago